NCT04668300 2026-04-15
DOSa
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT04705818 2026-03-06
CAIRE
Institut Bergonié
Phase 2 Completed
NCT04065269 2026-02-20
ATARI
Institute of Cancer Research, United Kingdom
Phase 2 Active not recruiting
NCT03851614 2026-02-09
DAPPER
University Health Network, Toronto
Phase 2 Active not recruiting
NCT03085225 2025-09-04
TRAMUNE
Institut Bergonié
Phase 1 Completed
NCT02815995 2025-06-12
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03912818 2023-09-11
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Stanford University
Phase 2 Terminated
NCT03317457 2023-06-15
MEDISARC
AIO-Studien-gGmbH
Phase 2 Completed
NCT03798106 2023-06-12
A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma
Yonsei University
Phase 2 Completed
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed